Univariate analysis of ISCL/EORTC T-stage classification and effect of histologic and biochemical factors on OS, DSS, and PFS
| OS | DSS | PFS | ||||
|---|---|---|---|---|---|---|
| Classification | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| T classification | ||||||
| T1a vs. T4 | 0.05 (0.03–0.09) | <0.0001 | 0.01 (0.01–0.075) | <0.0001 | 0.09 (0.05–0.14) | <0.0001 |
| T1b vs. T4 | 0.17 (0.11–0.28) | 0.21 (0.10–0.44) | 0.43 (0.30–0.62) | |||
| T2a vs. T4 | 0.08 (0.04–0.16) | 0.06 (0.02–0.19) | 0.14 (0.08–0.23) | |||
| T2b vs. T4 | 0.33 (0.23–0.47) | 0.31 (0.17–0.55) | 0.57 (0.43–0.77) | |||
| T3 vs. T4 | 0.68 (0.49–0.94) | 1 (0.62–1.61) | 0.75 (0.55–1.03) | |||
| N classification | ||||||
| N0 vs. N4 | 0.27 (0.17–0.45) | <0.0001 | 0.22 (0.10–0.46) | <0.0001 | 0.39 (0.24–0.62) | <0.0001 |
| N1 vs. N4 | 0.37 (0.19–0.75) | 0.32 (0.11–0.95) | 0.55 (0.29–1.04) | |||
| N2 vs. N4 | 0.98 (0.51–1.90) | 1.11 (0.42–2.92) | 0.99 (0.51–1.91) | |||
| N3 vs. N4 | 0.92 (0.40–2.13) | 1.09 (0.32–3.66) | 0.88 (0.38–2.03) | |||
| B classification | ||||||
| B0 vs. B2 | 0.19 (0.15–0.25) | <0.0001 | 0.21 (0.14–0.32) | <0.0001 | 0.29 (0.23–0.37) | <0.0001 |
| B1 vs. B2 | 0.11 (0.01–0.80) | 0.31 (0.04–2.27) | 0.51 (0.18–1.39) | |||
| M classification | ||||||
| M0 vs. M1 | 0.27 (0.19–0.38) | <0.0001 | 0.18 (0.11–0.29) | <0.0001 | 0.39 (0.28–0.54) | <0.0001 |
| Sezary syndrome | ||||||
| No vs. yes | 0.2 (0.15–0.25) | <0.0001 | 0.21 (0.14–0.31) | <0.0001 | 0.39 (0.28–0.54) | <0.0001 |
| Folliculotropic | ||||||
| No vs. yes | 1.19 (0.56–2.53) | 0.64 | 1.6 (0.39–6.5) | 0.5 | 1.07 (0.57–2.02) | 0.81 |
| Poikiloderma | ||||||
| No vs. yes | 2.83 (1.26–6.37) | 0.01 | 6.7 (0.94–48.65) | 0.06 | 1.63 (0.94–2.85) | 0.08 |
| Hypopigmented | ||||||
| No vs. yes | 1.56 (0.73–3.32) | 0.24 | 2.06 (0.50–8.39) | 0.3 | 1.51 (0.77–2.94) | 0.22 |
| MF with Lyp | ||||||
| No vs. yes | 5.58 (1.38–22.42) | 0.02 | 4.23 (0.59–30.3) | 0.15 | 2.76 (1.14–6.69) | 0.02 |
| LCT skin and node | ||||||
| No vs. yes | 0.13 (0.08–0.20) | <0.0001 | 0.06 (0.03–0.13) | <0.0001 | 0.33 (0.24–0.45) | <0.0001 |
| Tumor distribution | ||||||
| Localized vs. solitary | 0.81 (0.36–1.78) | <0.0001 | 0.77 (0.23–2.52) | <0.0001 | 1.06 (0.52–2.15) | <0.0001 |
| Regional vs. solitary | 0.87 (0.25–2.94) | 1.89 (0.51–7.02) | 0.73 (0.21–2.44) | |||
| Generalized vs. solitary | 1.34 (0.74–2.41) | 1.52 (0.65–3.56) | 1.17 (0.66–2.08) | |||
| LDH | ||||||
| Normal vs. high | 0.25 (0.19–0.32) | <0.0001 | 0.22 (0.15–0.34) | <0.0001 | 0.3 (0.24–0.37) | <0.0001 |
| WBC | ||||||
| Normal vs. high | 0.35 (0.25–0.48) | <0.0001 | 0.27 (0.16–0.44) | <0.0001 | 0.42 (0.31–0.56) | <0.0001 |
| Sex | ||||||
| Female vs. male | 0.84 (0.65–1.07) | 0.16 | 0.91 (0.16–1.36) | 0.67 | 0.87 (0.70–1.08) | 0.22 |
| β2-Microglobulin | ||||||
| <1.8 vs. >1.8 | 0.153 (0.08–0.26) | <0.0001 | 0.1 (0.03–0.28) | <0.0001 | 0.22 (0.14–0.34) | <0.0001 |
| CD25 expression | ||||||
| <20% vs. >20% | 0.81 (0.58–1.15) | 0.25 | 0.73 (0.44–1.19) | 0.21 | 0.76 (0.56–1.03) | 0.09 |
| CD30 expression | ||||||
| No vs. yes | 0.92 (0.57–1.49) | 0.76 | 0.98 (0.48–2.00) | 0.97 | 1.03 (0.67–1.59) | 0.87 |